"IMAT ONCOMEDICA S.A. es una institución privada que presta servicios de salud de alta complejidad en especialidades oncológicas y cardiovasculares."

During the past decade, Oncomedica S.A. conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 14 clinical trials were completed, i.e. on average, 53.8% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 10 clinical trials were completed. i.e. 83.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oncomedica S.A." #1 sponsor was "Hoffmann-La Roche" with 11 trials, followed by "Merck Sharp & Dohme LLC" with 6 trials sponsored, "Amgen" with 2 trials sponsored, "Bayer" with 2 trials sponsored and "Celgene" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oncomedica S.A." #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Foundation Medicine, Inc." with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "German Breast Group" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Oncomedica S.A." are "Breast Cancer" (4 trials), "Chemotherapy-induced Thrombocytopenia" (2 trials), "Coronavirus Disease (COVID-19)" (2 trials), "Prostatic Neoplasms" (2 trials) and "Acute Lymphoid Leukemia" (1 trials). Many other conditions were trialed in "Oncomedica S.A." in a lesser frequency.

Most popular intervention types in "Oncomedica S.A." are "Drug" (28 trials), "Biological" (5 trials) and "Other" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Paclitaxel" (6 trials), "Carboplatin" (5 trials), "Pembrolizumab" (5 trials) and "Docetaxel" (4 trials). Other intervention names were less common.

The vast majority of trials in "Oncomedica S.A." are 24 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Oncomedica S.A.". undefined are not yet recruiting, 7 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Oncomedica S.A., undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Oncomedica S.A., 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".